These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 26264400)

  • 1. Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitus.
    Werzowa J; Pacini G; Hecking M; Fidler C; Haidinger M; Brath H; Thomas A; Säemann MD; Tura A
    J Diabetes Complications; 2015; 29(8):1211-6. PubMed ID: 26264400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic management and clinical outcomes in underserved minority kidney transplant recipients with type 2 and posttransplantation diabetes: A single-center retrospective study.
    Aleksic S; Eisenberg R; Tsomos E; Zahedpour Anaraki S; Japp E; Upadhyay L; Mowrey WB; Akalin E; Zonszein J
    Diabetes Res Clin Pract; 2020 Jul; 165():108221. PubMed ID: 32442553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
    Chan CL; Pyle L; Kelsey MM; Newnes L; Baumgartner A; Zeitler PS; Nadeau KJ
    Pediatr Diabetes; 2017 Nov; 18(7):629-636. PubMed ID: 27873436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial.
    Schwaiger E; Krenn S; Kurnikowski A; Bergfeld L; Pérez-Sáez MJ; Frey A; Topitz D; Bergmann M; Hödlmoser S; Bachmann F; Halleck F; Kron S; Hafner-Giessauf H; Eller K; Rosenkranz AR; Crespo M; Faura A; Tura A; Song PXK; Port FK; Pascual J; Budde K; Ristl R; Werzowa J; Hecking M
    J Am Soc Nephrol; 2021 Aug; 32(8):2083-2098. PubMed ID: 34330770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among different glycemic variability indices obtained by continuous glucose monitoring.
    Saisho Y; Tanaka C; Tanaka K; Roberts R; Abe T; Tanaka M; Meguro S; Irie J; Kawai T; Itoh H
    Prim Care Diabetes; 2015 Aug; 9(4):290-6. PubMed ID: 25456706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis.
    Mirani M; Berra C; Finazzi S; Calvetta A; Radaelli MG; Favareto F; Graziani G; Badalamenti S
    Diabetes Technol Ther; 2010 Oct; 12(10):749-53. PubMed ID: 20809678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
    Wada N; Mori K; Nakagawa C; Sawa J; Kumeda Y; Shoji T; Emoto M; Inaba M
    J Diabetes Complications; 2015; 29(8):1310-3. PubMed ID: 26298521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.
    Pratley RE; Rosenstock J; Heller SR; Sinclair A; Heine RJ; Kiljański J; Brusko CS; Duan R; Festa A
    J Diabetes Sci Technol; 2018 Nov; 12(6):1184-1191. PubMed ID: 29893144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
    Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
    Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.
    Reed J; Dong T; Eaton E; Friswold J; Porges J; Al-Kindi SG; Rajagopalan S; Neeland IJ
    Diabetes Obes Metab; 2024 Jul; 26(7):2881-2889. PubMed ID: 38680050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB; Wang XQ; Chen JF; Wu G; Jin Y
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes.
    Anjana RM; Kesavadev J; Neeta D; Tiwaskar M; Pradeepa R; Jebarani S; Thangamani S; Sastry NG; Brijendra Kumar S; Ramu M; Gupta PPK; Vignesh J; Chandru S; Kayalvizhi S; Jagdish PS; Uthra SCB; Lovelena M; Jyoti S; Suguna Priya S; Kannan A; Mohan V; Unnikrishnan R
    Diabetes Technol Ther; 2017 Sep; 19(9):533-540. PubMed ID: 28930495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic variability during algorithmic titration of insulin among hospitalized patients with type 2 diabetes and heart failure.
    Dungan K; Binkley P; Osei K
    J Diabetes Complications; 2016; 30(1):150-4. PubMed ID: 26475503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
    Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
    Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The pharmacogenetics of hypoglycemia and the glycemic variability at the patients ith type 2 diabetes mellitus].
    Chernikova NA; Kamynina LL; Ametov AS; Sychev DA; Grishina EA; Ryzhikova KA
    Ter Arkh; 2020 Nov; 92(10):54-62. PubMed ID: 33346480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poststroke glycemic variability increased recurrent cardiovascular events in diabetic patients.
    Yoon JE; Sunwoo JS; Kim JS; Roh H; Ahn MY; Woo HY; Lee KB
    J Diabetes Complications; 2017 Feb; 31(2):390-394. PubMed ID: 27956053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.
    Owens DR; Monnier L; Hanefeld M
    Diabetes Obes Metab; 2017 Dec; 19(12):1645-1654. PubMed ID: 28474401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.